ANNOUNCEMENT

MedCity CONVERGE July 9-10 in Philly gathers payers, providers, medtech, pharma, digital health, policymakers & more.

Goldman Sachs Reiterates Sell Rating, Lowers PT on Aetna

August 1, 2012 12:21 pm by | 0 Comments

insurance, medical insurance, healthcare reform

In a report published Wednesday, the Goldman Sachs Group reiterated its Sell rating on Aetna (NYSE: AET), but lowered its price target from $43.00 to $41.00.

Goldman Sachs noted, “So far, Aetna's deliberate shift to modestly lower margins seems to have been well executed and has helped Aetna grow c-risk enrollment where both UNH and WLP have shown substantial erosion. That said, to our view there is considerable downside risk as Aetna moves ahead with this strategy amidst pricing pressures from other plans in an environment of modestly rising medical cost trend. For now, our revised 2013E-2014E EPS reflects margin pressure but still positive earnings growth.”

Aetna closed on Tuesday at $36.06.

(c) 2012 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Copyright 2013 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Related Topics: , ,

By Einhorn, Dwight

Visit website | More posts by Author

0 comments

Stay Up To Date

Recent Comments

Research Center

Jobs Board

Next Story
Pfizer coping well with loss of Lipitor patent, so what’s the outlook for blockbuster replacements?
Close